新闻通稿

主页/新闻通稿

Oramed Letter to Shareholders

$169 Million in Cash and Investments Pivotal Phase 3 Oral Insulin Data Expected January 2023 Phase 2 NASH Data Expected This Quarter Oravax - Oral Vaccine NEW YORK, July 7, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company [...]

2022-07-07T07:55:00+00:00分类:新闻通稿|标签:|

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

NEW YORK, May 24, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled [...]

2022-05-24T08:10:00+00:00分类:新闻通稿|标签:|

Oramed Granted NASH Patent in Europe

NEW YORK, April 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company the patent titled "Methods and Compositions for Treating NAFLD, Hepatic [...]

2022-04-05T08:25:00+00:00分类:新闻通稿|标签:|